Review Article

The Biological Mechanisms of Frailty: Focusing on Cellular Senescence

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image

  • Views: 157

  • Likes: 2

  • Downloads: 15

  • Read time: 31m 40s
Average (ratings)
No ratings
Your rating

Abstract

Frailty is a multifaceted clinical syndrome characterised by diminished physiological reserve and heightened vulnerability to stressors, predominantly affecting older adults. Increasing evidence implicates cellular senescence (a largely irreversible state of cell-cycle arrest accompanied by the senescence-associated secretory phenotype) as a central mechanistic driver in the pathogenesis of frailty. The aim of this review is to provide an overview of cellular senescence and examine how the accumulation of senescent cells across multiple organ systems disrupts tissue homeostasis, thereby promoting systemic inflammation and functional decline. Within this context, the role of circulating senescence-associated secretory phenotype factors as both drivers and potential biomarkers of frailty is explored. Furthermore, this review discusses the potential of emerging interventions targeting the senescent cell burden (senolytic and senomorphic agents) and nonpharmacological approaches to mitigate frailty-associated functional decline. Finally, the clinical implications of linking cellular senescence to frailty are outlined, and key priorities for future research aimed at improving risk stratification and therapeutic intervention are highlighted.

Keywords

Frailty, cell senescence, secretory phenotype, inflammation, biomarker, senotherapeutic,

Received:

Accepted:

Published online:

DOI: https://doi.org/10.15420/ecr.2025.81

Disclosure: JDE has no conflicts of interest to declare.

Acknowledgements: Elements of Figure 1 were generated with assistance from ChatGPT (OpenAI). The author reviewed and edited all the figure content.

Correspondence: Jorge D Erusalimsky, Cardiff Metropolitan University, Llandaff Campus, Western Ave, Cardiff CF5 2YB, UK. E: jderusalimsky@cardiffmet.ac.uk

Copyright:

© The Author(s). This work is open access and is licensed under CC-BY-NC 4.0. Users may copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Frailty is a complex clinical condition of diminished physiological reserves and function which primarily affects older adults.1,2 Frailty increases these individuals’ vulnerability to everyday stressors, placing them at an enhanced risk of dependency, disability, hospitalisation and death.2,3 In a quest to identify and understand the development of this condition two main conceptual models of frailty have been developed: the frailty phenotype (FP) and the frailty index (FI) of cumulative health deficits.2,4 The FP defines frailty as a biological syndrome displaying specific physical manifestations, which may or may not co-exist with the presence of chronic diseases.4 It consists of five components (weight loss, low physical activity, exhaustion, slowness and weakness), with individuals who experience three or more of these symptoms being considered frail.1 In contrast, the FI looks at frailty beyond physical characteristics, considering this condition a state of poor health that is the result of an accumulation of ageing-related deficits (symptoms, laboratory tests, disabilities and diseases).5 As a diagnostic tool the FI computes the accumulation of at least 30 health deficits.6 Other definitions of frailty emphasise the multidimensional nature of this condition, taking into account that decrements in several domains of human functioning (physical, cognitive, psychological and social) may play a role in its development.7 The multidimensional nature of frailty is in part accountable for the plethora of diagnostic tools that have been developed to detect this condition.8 However, Rockwood’s FI and Fried’s FP with variations thereof, remain the two most used instruments in research and clinical practice to detect frailty at present.1,5 Despite their differences, these models often identify overlapping groups of frail older adults, suggesting that a unified concept of frailty underlies them.

At the pathophysiological level, frailty involves the dysregulation of multiple interconnected biological processes, primarily those that affect inflammation, stress responses, energy metabolism, endocrine regulation, neurological and musculoskeletal functions.2,4 Several key interconnected molecular, cellular and systemic hallmarks of ageing, are likely to contribute to this complex pathophysiological scenario.9 Indeed, increasing evidence points to a link between the pathophysiology of frailty and these hallmarks, namely genetic instability, telomere attrition, epigenetic changes, impaired autophagy, loss of proteostasis, dysregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, altered intercellular communication, stem cell exhaustion, microbiome imbalance and chronic inflammation.10–22 In this review, I focus on cellular senescence as a major underlying mechanism in the development of frailty. I describe the contribution of tissue-specific and systemic effects of senescent cells to the loss of homeostasis and functional decline characteristic of this condition and further explore the role of circulating senescence-associated secretory phenotype (SASP) factors as both drivers and potential biomarkers of frailty. Finally, I discuss the evidence that supports the use of pharmacological and lifestyle interventions to tackle frailty by targeting the harmful effects of senescent cells.

Cellular Senescence and the Senescent Phenotype

Cellular senescence is a damage and stress response recognised by distinctive changes in gene expression, cellular morphology and function, collectively referred to as the ‘senescent phenotype’. Initially limited to mitotically competent cells, this phenomenon was defined as an irreversible state of growth arrest that manifested as a result of repeated cell divisions (i.e. replicative senescence), or that ensued from stressful conditions, such as exposure to genotoxic and oxidative agents, nutrient deprivation and/or oncogene activation (stress-induced senescence).23,24 Later on it was shown that cellular stress can also induce a senescent phenotype in cells that do not normally divide, including neurons, cardiomyocytes, skeletal muscle cells and osteocytes.25

In both mitotic and postmitotic cells the senescent phenotype is characterised by distinctive molecular, biochemical, morphological and functional features.26 These include telomere damage, persistent DNA damage signalling, increased expression of the cell-cycle inhibitors p21 and p16, mitochondrial dysfunction, increased generation of reactive oxygen species, changes in chromatin structure, cellular hypertrophy, increase in lysosomal mass and profound changes in the secretome. This secretome, the SASP, is heterogeneous and context dependent, and includes a variety of cytokines (e.g. interleukin [IL]-1, IL-6, IL-8, tumour necrosis factor [TNF]-α), chemokines (e.g. C-C ligand 2 [CCL2], C-X-C ligand 1 [CXCL1]), proteases (e.g. matrix metalloproteinase 1 [MMP-1], cathepsin B), growth factors (e.g. transforming growth factor [TGF]-β, growth differentiation factor [GDF]-15, vascular endothelial growth factor [VEGF]-A), inhibitory molecules (e.g. plasminogen activator inhibitor [PAI]-1, insulin-like growth factor binding proteins [IGFBPs]) and bioactive exosomes, which are regarded as central to the role of senescence in normal physiology and pathophysiology.27,28

Cellular Senescence as a Driver of Frailty

Cellular senescence can serve a physiological role, for example in organismal development, tissue repair or tumour suppression.28 In this case, senescent cells promote their own elimination by macrophages, neutrophils and T-cells to maintain tissue integrity. However, with ageing the combined effect of cellular damage build-up and the age-associated decline in immunosurveillance leads to their accumulation in different tissues across the organism.28 As a result, senescent cells impair homeostasis, contributing to the deterioration of body functions and to the development of ageing-related pathologies.24,28,29

A causal link between cellular senescence and frailty is mostly supported by studies in mice.18 Mouse models carrying suicide transgenes encoding conditional pro-apoptotic enzymes under the control of a p16 or p21 promoter, allow for selective elimination of senescent cells.30 Experiments with these transgenic mice provide strong evidence that the removal of senescent cells attenuates physical and cognitive aspects of frailty.18 In addition, interventions with senotherapeutics, including agents that preferentially eliminate senescent cells (senolytics) or that suppress the SASP (senomorphics) had similar effects, further supporting a causal relationship.18 Conversely, senescent cell transplantation or overexpression of p16 and p21 to increase senescence were shown to promote frailty characteristics.31,32 Taken together, experiments in animal models showed that senescent cell burden correlated with the severity of the functional decline, most consistently affecting strength, endurance, mobility and cognition.

In humans, however, the evidence for a role of cellular senescence in the pathophysiological changes underlying the development of frailty is circumstantial, emanating from the following lines of evidence:

  • With ageing, different tissues show an increase of senescent cells, with some studies reporting that this increase was exacerbated by sedentarity.33–37
  • Higher mRNA levels of the senescent cell marker p16 in blood T-lymphocytes and shorter telomeres in circulating leukocytes are associated with measures of frailty.38,39
  • Increased blood levels of multiple SASP components, which are regarded as biomarkers of senescent cell burden, are associated with frailty or poor physical and/or cognitive function in cross-sectional and longitudinal cohort studies.27,40–43
  • In an interventional human study, a structured exercise programme administered to a group of older adults lowered biomarkers of senescent cell burden, including the expression of genes that orchestrate the senescence programme, such as p16 p21, cyclic GMP-AMP synthase and TNF-α in T-lymphocytes, as well as circulating concentrations of SASP factors. At the same time, this intervention also improved objective measures of muscle performance and physical function as well as subjective measures of fatigue and well-being.44

As discussed below, cellular senescence is thought to contribute to the development and manifestations of frailty through both tissue-specific and systemic effects.

Tissue-specific Effects of Cellular Senescence Contributing to Frailty

Two features of cellular senescence are responsible for its tissue-specific consequences. The first one is the permanent proliferative arrest, which directly compromises the regenerative and repair capacity of tissues and organs. In this context, the contribution of oxidative stress-induced senescence in tissue-resident stem cells could also play an important role.20 The second one is the release of cell type-specific SASP components, which disrupt tissue homeostasis and function by inducing local inflammation, tissue remodelling, cell loss and fibrosis.27,28 The musculoskeletal, cardiovascular and immune systems have been traditionally considered as the main protagonists through which cellular senescence makes a meaningful contribution to the development and progression of frailty. As summarised below, other organs, including the brain, lung, liver, kidney and adipose tissue, have been demonstrated to also play important roles. A diagram linking cellular senescence in different tissues and organs to the manifestations of frailty is shown in Figure 1.

Figure 1: Impact of Cellular Senescence on the Development of Frailty

Article image
Download

Musculoskeletal System

The age-related accumulation of senescent cells in muscle, bone and cartilage has several detrimental effects on these tissues. It impairs myogenesis, increases fibrosis and promotes skeletal muscle atrophy.30 It also induces degradation of bone and cartilage.45 These processes collectively lead to sarcopenia, osteoporosis and osteoarthritis, which in turn result in reduced strength, impaired mobility and an increased risk of falls and fractures.46

Heart

Ageing and frailty are associated with subclinical alterations in cardiac structure and function.47–49 These changes, which limit the functional reserve of the ageing heart, also underlie the susceptibility to heart failure (HF).50,51 In fact, HF and frailty frequently coexist, with the former increasing the risk of developing the latter.47,52 These associations suggest that frailty and HF may share common biological drivers, including mitochondrial dysfunction and the induction of cardiomyocyte senescence.51

Cardiomyocytes showing a senescence-like phenotype have been described in the hearts of aged humans and mice.53 The onset of senescence in these cells appears to be triggered by persistent DNA damage at telomeric regions, which seems to occur independently of cell division or telomere shortening. Instead, it is thought to be driven by mitochondrial dysfunction-induced oxidative stress.53 Senescent cardiomyocytes show a non-canonical SASP that promotes myofibroblast activation and cardiac hypertrophy, directly contributing to age-related cardiac remodelling and dysfunction.53 Indeed, clearance of senescent cells in mice hearts alleviates myocardial hypertrophy and fibrosis, demonstrating a causal role of cardiomyocyte senescence in age-related cardiac decline.53 Senescent cardiomyocytes are also present in failing human hearts, although in this case, together with the presence of extensive DNA damage, telomeres have been reported to be shorter.54

Senescence of cardiac stem cells has been suggested as a factor contributing to cardiac decline and HF. However, considering that the contribution of these cells to adult myocardial homeostasis is negligible, the potential role of cardiac stem cell senescence to HF and frailty remains unclear.51

Vasculature

Extensive evidence supports the notion that senescent endothelial and vascular smooth muscle cells accumulate in the ageing vasculature.29,50,55 These cells contribute to a decline in vascular reactivity, to vascular stiffening, calcification and local inflammation, thus compromising tissue perfusion, as well as supporting the development and progression of atherosclerosis.50,55,56 The systemic repercussions of these pathophysiological changes, together with the decrease in heart function, can in turn be a cause of fatigue, muscle weakness, reduced exercise tolerance and loss of resilience, and may explain the reported associations between subclinical cardiovascular disease and frailty.47,57,58

Different phenotype features of senescent vascular cells are likely to contribute to this pathophysiological scenario. For example, for endothelial cells, the loss of replicative capacity weighs against the integrity of the endothelium and impairs successful physiological angiogenesis, which may slow wound healing and recovery from stress.59 In addition, senescent endothelial cells produce less nitric oxide (NO) and more reactive oxygen species, resulting in a reduction in NO bioavailability and thereby impairing vasodilation.59 They also express chemokines (e.g. CXCL1), adhesion molecules (e.g. the intercellular, vascular cell, and platelet endothelial cell adhesion molecules ICAM-1, VCAM-1 and PECAM-1) and PAI-1, which promote leukocyte adhesion, vascular leakage, atherosclerotic plaque formation and activation of the coagulation cascade.59,60 In vascular smooth muscle cells, their senescent phenotype plays an active role in promoting vascular calcification via secretion of SASP factors, including IL-6, bone morphogenetic protein-2 and osteoprotegerin.61 In addition, they contribute to atherosclerotic plaque instability by driving plaque inflammation and matrix degradation as well as preventing plaque repair.55,62

Brain

The ageing brain shows the presence of senescent neurons and their precursors, as well as astrocytes, microglia and microvascular endothelial cells.63,64 This accumulation contributes to neuroinflammation, impaired neurogenesis, as well as synaptic and blood–brain barrier dysfunction, all of which contribute to cognitive decline. This notion is supported by experimental studies in rodents that demonstrate that clearing senescent cells in the brain (genetically or with senolytics) reduces neuroinflammation and improves cognitive function, thus linking brain cell senescence to frailty outcomes.65,66

In the particular case of neurons, cellular senescence may in fact play a wider role in the development of frailty. With advancing age, neurons have morphological and functional alterations alongside changes in proteostasis, redox balance and calcium dynamics that could push them to acquire senescent phenotypes.63 These changes not only affect cognitive functions but also contribute to the declining motor and sensory functions commonly observed in elderly frail individuals.

Lungs

Lung cells are particularly vulnerable to senescence-inducing stimuli due to their exposure to noxious environmental conditions and the relatively high ambient oxygen concentration. Accumulation of senescent cells in the lungs disrupts normal function primarily by two interdependent processes: first, by preventing tissue self-repair, eventually causing breakdown of the air sacks, and second, by promoting tissue scarring and fibrosis, leading to a progressive loss of lung elasticity.67 Poor lung function has systemic consequences. It causes tissue hypoxia, which impairs ATP production, leading to fatigue, weakness, physical inactivity and sarcopenia. Consistent with these pathophysiological effects, poor lung function has been associated with the acceleration of cognitive decline as well as with the development and progression of physical frailty.68,69

Adipose Tissue

Adipose tissue is both a metabolic and endocrine organ, playing a central role in energy balance, inflammation and systemic homeostasis.70 In ageing and obesity, white adipose depots accumulate senescent pre-adipocytes.70,71 These cells secrete activin A and other SASP factors that cause defective adipogenesis, ectopic lipid deposition, insulin resistance and inflammation.71 These pathophysiological changes have systemic consequences by altering the energy balance of the organism and promoting physical dysfunction, thereby playing a major role in the development of frailty.31

Liver

Senescent cells accumulate in the liver with ageing, obesity, diabetes and chronic liver diseases.72 Senescent hepatocytes lose key liver functions and secrete pro-inflammatory and pro-fibrotic factors that disrupt tissue homeostasis by promoting inflammation, fibrosis and regenerative failure in the liver itself.72,73 These local changes cause systemic metabolic imbalances and impaired detoxification, which weaken physiological resilience. In addition, with advanced liver dysfunction or liver disease, the impairment of hepatic synthetic function may potentially result in malnutrition and in an impairment of the skeletal muscle protein synthetic response, rapidly leading to progressive muscle breakdown, further accelerating frailty.

Kidneys

Senescent tubular epithelial cells, endothelial cells and podocytes accumulate in the kidneys with ageing. The irreversible cell-cycle arrest of senescent epithelial cells, impinges on the capacity for tissue self-repair while the secretion of pro-inflammatory and pro-fibrotic SASP factors, sustains local inflammation and fibrosis. The consequences of these alterations reduce the kidney filtration capacity, impairing its systemic detoxifying function.74 Cellular senescence also downregulates kidney production of Klotho, an anti-ageing protein, which among other functions inhibits vascular ageing.75 Ultimately, senescence-driven renal dysfunction may lead to uremic inflammation and its systemic consequences, including promoting malnutrition, sarcopenia, fatigue and vulnerability to stressors.76 In agreement with this scenario, impaired renal function has been shown to be associated with both the prevalence and incidence of frailty.48,77

Immune System

Unbalanced haematopoietic stem cell (HSC) homeostasis and senescence of T-cells are two major phenomena implicated in the age-associated decline of adaptive immune function, which is marked by a high vulnerability to infections and vaccine failure in older adults. HSCs undergo alterations with age due to intrinsic processes such as accumulation of DNA damage, mitochondrial dysfunction, decreased proteostasis and epigenetic reprogramming and also through extrinsic factors resulting from changes taking place primarily in the bone marrow niche.78 As a result, HSCs show a reduced capacity to self-renew and a bias towards myeloid differentiation, leading to an overall decline in adaptive immunity. Similarly, with repeated stimulation across the life course, T-cells undergo excessive telomere shortening and/or DNA damage, resulting in poor proliferative capacity, weakened antigen-specific responses and pro-inflammatory gene expression, thus potentially contributing to the pathophysiology of frailty.79 In support of this possibility, a strong association between T-cell senescence and physical frailty was reported in the Singapore Longitudinal Ageing Study.80

Resident macrophages also appear to undergo molecular and phenotypic changes with ageing that are akin to cellular senescence and that are partly induced through contact with other senescent cells.81 These macrophages show decreased levels of autophagy, which impair their ability to clear damaged cells, thus affecting the intricate balance required for tissue homeostasis.81

Systemic Impact of SASP Factors on Frailty

Secretion of pro-inflammatory SASP components serves as the primary mechanism through which the senescent cells present in different organs exert their systemic effects.28 These factors initially create a pro-inflammatory microenvironment by recruiting and activating immune cells. This initial activity leads to further release of inflammatory mediators and amplification of the inflammatory response. SASP factors can also dysregulate the response of immune cells, which can lead to poor immunosurveillance and the impairment of senescent cell clearance. In addition, they can also induce secondary senescence in both adjacent and distant non-senescent cells, creating a ‘contagious’ process that rapidly propagates cellular dysfunction throughout the organism.82,83 This cascade phenomenon explains how relatively small populations of senescent cells may contribute significantly to the chronic, low-grade inflammation that develops with advancing age (coined ‘inflammageing’), and the multisystem physiological decline characteristic of frailty.84

SASP Factors as Biomarkers of Frailty

Multiple studies have explored the association of circulating SASP factors with the prevalence and incidence of frailty, as well as their related physical and cognitive components, and/or their outcomes (Supplementary Table 1). These studies not only point to the presumptive role of these factors as drivers of frailty but also underscore their potential as clinical biomarkers that could help with the assessment of risk, the diagnosis and prognosis of the condition, and with monitoring the effect of treatment interventions. Prominent among these factors is GDF-15, a multifunctional stress-induced protein involved in the regulation of appetite, bodyweight, the immune response and inflammation.85 GDF-15 is also a marker of mitochondrial dysfunction in skeletal muscle and is emerging as a key player in the promotion of age-related sarcopenia.86 Accordingly, multiple studies (Supplementary Table 1) have consistently reported that elevated blood levels of GDF-15 are associated with prevalent or incident frailty, and/or with frailty-contributing physical–cognitive decrements.40,42,87–93 In addition, GDF-15 has been shown to predict further functional deterioration and death.43,88,94

Another SASP factor extensively studied in the context of frailty is IL-6 (Supplementary Table 1). This cytokine plays an important role in the regulation of inflammation and skeletal muscle metabolism. Excessive or chronic increases of IL-6 under conditions of systemic inflammation impair muscle regenerative processes and contribute to muscle degradation and sarcopenia.95 Thus, like GDF-15, an increase in IL-6 may be an important mediator by which cellular senescence and the SASP contribute to the development of frailty. It should be stressed, however, that an increase in circulating SASP factors, including IL-6 and GDF-15, may be associated with other age-related conditions including HF, coronary heart disease, stroke and dementia, independently of the presence of frailty.96 Equally, components of the SASP are also produced by a variety of non-senescent cells under different pathophysiological scenarios, for example during immune system activation, tissue remodelling in response to injury, as well as in cardiometabolic and other systemic stressful conditions, where they may overlap with senescent cell-mediated signalling.97

Different combinations of SASP factors (e.g. activin A, CCL3, Col6a3, FAS, GDF-15, IL-6, IL-15, MMP-7, osteopontin [OPN], TNFR-1, VEGF-A) have been incorporated into composite biomarker signatures that can predict frailty, as well as mobility disability, medical risk or mortality among pre-frail and frail individuals.40,41,88,98 This combined detection of multiple SASP factors may improve their diagnostic and prognostic accuracy, highlighting their potential clinical application.

Interventions to Tackle Frailty

Interventions to tackle frailty that target the harmful effects of senescent cells can be broadly divided into two categories: pharmacological therapy aimed directly at senescent cells, and non-pharmacological approaches that, although not primarily directed against these cells, may nonetheless influence senescence-related pathways.

Pharmacological Interventions Targeting Senescent Cells

Pharmacological interventions that directly target senescent cells have been explored for their potential effects on frailty.18 Preclinical studies in animal models of ageing show that senolytic treatments (such as a combination of dasatinib plus quercetin or the flavonoid fisetin), as well as use of the senomorphic agent metformin, reduce FI scores, slow the rate of frailty progression or improve physical–functional measures (grip strength, motor and cognitive performance).31,99,100

Early-phase pilot human studies with senolytics have also been conducted. These studies have shown reductions in senescent cell burden and circulating SASP biomarkers in diabetic kidney disease as well as improvements in physical function in idiopathic pulmonary fibrosis.101,102 However, larger human studies specifically designed to assess the effects of senotherapeutics on frailty are still in the early stages and have yet to provide definitive results.

Non-pharmacological Interventions with Potential Effects on Senescent Cells

Non-pharmacological interventions, including structured physical exercise programmes and nutritional approaches, have shown that frailty can be prevented or mitigated, especially when tackled in its early stages.103–105 Although these interventions are not primarily designed to target senescent cells, circumstantial evidence suggests that they may act in part by protecting against oxidative stress, reducing the senescent cell burden and attenuating chronic inflammation.106–108 Recent studies in older adults also indicate that higher levels of physical activity and function are associated with lower serum levels of SASP factors.43,44,109

Low vitamin D levels are associated with an increased risk of frailty. Conversely, increasing its levels may help to improve frailty status.110 In this context, it is noteworthy that vitamin D supplementation has been recently shown to reduce telomere attrition, suggesting a potential role in combating frailty by counteracting telomere erosion-induced senescence.111

Clinical Implications

The growing evidence linking cellular senescence to frailty has several important clinical implications for the assessment, prevention and treatment of this condition in older adults.

First, the consequences of senescent cell accumulation across multiple organs help to explain the heterogeneity of frailty presentations observed in clinical practice and provide clinicians with a biologically coherent basis to understand the multidimensional nature of this condition.

Second, as listed in Supplementary Table 1, circulating SASP factors show consistent associations with frailty, cognitive and physical decline, mobility disability and mortality across multiple cohort studies. These findings suggest that SASP-based biomarker panels could aid clinical risk stratification. Indeed, composite signatures integrating multiple SASP factors appear to improve diagnostic and prognostic accuracy, raising the possibility that this type of laboratory-based tool could be used in the future to support clinical decision-making in geriatric assessment.40,41,88

Third, pharmacological interventions with senotherapeutics have shown promising effects in preclinical and early-phase human studies.31,99,100–102 Although not yet ready for clinical implementation, these findings indicate a plausible therapeutic avenue for future frailty management.

Fourth, structured physical activity programmes reduce biomarkers of cellular senescence and improve physical function and well-being, supporting their role as a first-line intervention for frailty prevention and treatment.43,44,108 Furthermore, nutritional factors, such as maintaining adequate vitamin D levels, may also influence senescence-related pathways, suggesting opportunities for integrated lifestyle-based strategies.107,111

Finally, the recognition that cellular senescence emerges not only as a biological hallmark of ageing but also as a unifying biological mechanism driving the multisystem deterioration underlying frailty, encourages a shift toward earlier detection of this condition, when interventions may be most effective. Given that senescent cell burden accumulates with age and is exacerbated by conditions such as sedentarity and metabolic dysfunction, clinicians may increasingly view frailty as a modifiable condition rather than an inevitable consequence of ageing.

In summary, the integration of cellular senescence biology into clinical geriatric practice has the potential to refine frailty assessment, expand therapeutic options and improve patient outcomes. Continued translational research is essential before these insights can be fully implemented at the bedside, but the mechanistic clarity provided by cellular senescence research represents a significant step forward for the field.

Future Research Directions

The above insights highlight several key avenues for future investigation. Although animal models provide strong causal support for senescent cells as drivers of frailty, human data remain largely correlative, underscoring the need for longitudinal studies that track senescent cell burden, SASP profiles and clinical outcomes across ageing populations. Developing high-specificity, high-sensitivity biomarker panels is an important priority, particularly given the heterogeneity of SASP components and the fact that many are also produced by non-senescent cells under other stress conditions. Composite biomarkers have shown promise, but further refinement and clinical validation are required to determine their utility across diverse settings and comorbidities. The integration of predictive artificial intelligence platforms and wearable biosensor technologies with biomarker analysis could aid in these endeavours.112

Therapeutically, frailty-focused clinical trials of senotherapeutics are essential to determine efficacy, safety and optimal treatment regimens across the frailty continuum. Future investigations must also account for the diversity of senescent cell phenotypes, which may require the tailoring of therapy to specific tissues or senescence subtypes. Non-pharmacological interventions represent another promising frontier. Well-designed mechanistic trials in closely followed cohorts integrating exercise, nutritional optimisation and measurement of senescence-related pathways could clarify the extent to which lifestyle approaches can slow or reverse frailty trajectories.

Conclusion

Cellular senescence has emerged as a central biological mechanism underpinning the pathophysiology of frailty, linking molecular ageing processes to systemic functional decline. Through the accumulation of senescent cells and the propagation of the SASP, local tissue dysfunction is amplified into organism-wide inflammation and diminished resilience. Although animal studies provide compelling causal evidence, human data remain largely correlative and mechanistically incomplete. Further research is needed, integrating longitudinal biomarker studies and larger clinical trials of senescence-targeting interventions in well characterised cohorts of older adults. Clinical translation with senolytics and senomorphics remains challenging, due primarily to the molecular diversity of the senescent phenotype. Ultimately, the integration of senescence research into frailty medicine will require interdisciplinary collaboration across geroscience, epidemiology, exercise and nutrition science, digital health, geriatrics and clinical pharmacology. Such efforts may eventually enable the development of more targeted strategies to prevent, delay or reverse frailty by restoring cellular and systemic homeostasis.

Click here to view Supplementary Material.

References

  1. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–56. 
    Crossref | PubMed
  2. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet 2013;381:752–62. 
    Crossref | PubMed
  3. Kojima G, Iliffe S, Walters K. Frailty index as a predictor of mortality: a systematic review and meta-analysis. Age Ageing 2018;47:193–200. 
    Crossref | PubMed
  4. Fried LP, Cohen AA, Xue QL, et al. The physical frailty syndrome as a transition from homeostatic symphony to cacophony. Nat Aging 2021;1:36–46. 
    Crossref | PubMed
  5. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci 2007;62:722–7. 
    Crossref | PubMed
  6. Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a frailty index. BMC Geriatr 2008;8:24. 
    Crossref | PubMed
  7. Pilotto A, Custodero C, Maggi S, et al. A multidimensional approach to frailty in older people. Ageing Res Rev 2020;60:101047. 
    Crossref | PubMed
  8. Dent E, Martin FC, Bergman H, et al. Management of frailty: opportunities, challenges, and future directions. Lancet 2019;394:1376–86. 
    Crossref | PubMed
  9. López-Otín C, Blasco MA, Partridge L, et al. Hallmarks of aging: an expanding universe. Cell 2023;186:243–78. 
    Crossref | PubMed
  10. Sánchez-Flores M, Marcos-Pérez D, Lorenzo-López L, et al. Frailty syndrome and genomic instability in older adults: suitability of the cytome micronucleus assay as a diagnostic tool. J Gerontol A Biol Sci Med Sci 2018;73:864–72. 
    Crossref | PubMed
  11. Bountziouka V, Nelson CP, Codd V, et al. Association of shorter leucocyte telomere length with risk of frailty. J Cachexia Sarcopenia Muscle 2022;13:1741–51. 
    Crossref | PubMed
  12. Mak JKL, Skovgaard AC, Nygaard M, et al. Epigenome-wide analysis of frailty: results from two European twin cohorts. Aging Cell 2024;23:e14135. 
    Crossref | PubMed
  13. Aas SN, Hamarsland H, Cumming KT, et al. The impact of age and frailty on skeletal muscle autophagy markers and specific strength: a cross-sectional comparison. Exp Gerontol 2019;125:110687. 
    Crossref | PubMed
  14. Mladenovic Djordjevic AN, Kapetanou M, Loncarevic-Vasiljkovic N, et al. Pharmacological intervention in a transgenic mouse model improves Alzheimer’s-associated pathological phenotype: involvement of proteasome activation. Free Radic Biol Med 2021;162:88–103. 
    Crossref | PubMed
  15. Yeap BB, Paul Chubb SA, Lopez D, et al. Associations of insulin-like growth factor-I and its binding proteins and testosterone with frailty in older men. Clin Endocrinol (Oxf) 2013;78:752–9. 
    Crossref | PubMed
  16. Roichman A, Elhanati S, Aon MA, et al. Restoration of energy homeostasis by SIRT6 extends healthy lifespan. Nat Commun 2021;12:3208. 
    Crossref | PubMed
  17. Mau T, Barnes HN, Blackwell TL, et al. Lower muscle mitochondrial energetics is associated with greater phenotypic frailty in older women and men: the Study of Muscle, Mobility and Aging. GeroScience 2024;46:2409–24. 
    Crossref | PubMed
  18. Marcozzi S, Bigossi G, Giuliani ME, et al. Cellular senescence and frailty: a comprehensive insight into the causal links. GeroScience 2023;45:3267–305. 
    Crossref | PubMed
  19. Sanz-Ros J, Romero-García N, Mas-Bargues C, et al. Small extracellular vesicles from young adipose-derived stem cells prevent frailty, improve health span, and decrease epigenetic age in old mice. Sci Adv 2022;8:eabq2226. 
    Crossref | PubMed
  20. Lawton A, Tripodi N, Feehan J. Running on empty: exploring stem cell exhaustion in geriatric musculoskeletal disease. Maturitas 2024;188:108066. 
    Crossref | PubMed
  21. Xu Y, Wang Y, Li H, et al. Altered fecal microbiota composition in older adults with frailty. Front Cell Infect Microbiol 2021;11:696186. 
    Crossref | PubMed
  22. Walker KA, Walston J, Gottesman RF, et al. Midlife systemic inflammation is associated with frailty in later life: the ARIC study. J Gerontol A Biol Sci Med Sci 2019;74:343–9. 
    Crossref | PubMed
  23. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965;37:614–36. 
    Crossref | PubMed
  24. Campisi J, d’Adda di Fagagna FF. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729–40. 
    Crossref | PubMed
  25. Sapieha P, Mallette FA. Cellular senescence in postmitotic cells: beyond growth arrest. Trends Cell Biol 2018;28:595–607. 
    Crossref | PubMed
  26. Gasek NS, Kuchel GA, Kirkland JL, Xu M. Strategies for targeting senescent cells in human disease. Nat Aging 2021;1:870–9. 
    Crossref | PubMed
  27. Basisty N, Kale A, Jeon OH, et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLOS Biol 2020;18:e3000599. 
    Crossref | PubMed
  28. Wang B, Han J, Elisseeff JH, Demaria M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat Rev Mol Cell Biol 2024;25:958–78. 
    Crossref | PubMed
  29. Erusalimsky JD, Kurz DJ. Cellular senescence in vivo: its relevance in ageing and cardiovascular disease. Exp Gerontol 2005;40:634–42. 
    Crossref | PubMed
  30. Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011;479:232–6. 
    Crossref | PubMed
  31. Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med 2018;24:1246–56. 
    Crossref | PubMed
  32. Franco AC, Martini H, Victorelli S, et al. Senescent cell transplantation into the skin induces age-related peripheral dysfunction and cognitive decline. Aging Cell 2025;24:e14340. 
    Crossref | PubMed
  33. Liu Y, Sanoff HK, Cho H, et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell 2009;8:439–48. 
    Crossref | PubMed
  34. Bhat R, Crowe EP, Bitto A, et al. Astrocyte senescence as a component of Alzheimer’s disease. PLOS One 2012;7:e45069. 
    Crossref | PubMed
  35. Sousa-Victor P, Gutarra S, García-Prat L, et al. Geriatric muscle stem cells switch reversible quiescence into senescence. Nature 2014;506:316–21. 
    Crossref | PubMed
  36. Rossman MJ, Kaplon RE, Hill SD, et al. Endothelial cell senescence with aging in healthy humans: prevention by habitual exercise and relation to vascular endothelial function. Am J Physiol Heart Circ Physiol 2017;313:H890–5. 
    Crossref | PubMed
  37. Idda ML, McClusky WG, Lodde V, et al. Survey of senescent cell markers with age in human tissues. Aging (Albany, NY) 2020;12:4052–66. 
    Crossref | PubMed
  38. El Jurdi N, Te HS, Cao Q, et al. Frailty and pre-frailty associated with long-term diminished physical performance and quality of life in breast cancer and hematopoietic cell transplant survivors. Aging (Albany, NY) 2024;16:12432–42. 
    Crossref | PubMed
  39. Jian X, Sun W, Zhang J, et al. Frailty mediating the causality between leucocyte telomere length and mortality: a cohort study of 440,551 UK Biobank participants. EPMA J 2024;15:99–110. 
    Crossref | PubMed
  40. Schafer MJ, Zhang X, Kumar A, et al. The senescence-associated secretome as an indicator of age and medical risk. JCI Insight 2020;5:e133668. 
    Crossref | PubMed
  41. Fielding RA, Atkinson EJ, Aversa Z, et al. Associations between biomarkers of cellular senescence and physical function in humans: observations from the Lifestyle Interventions for Elders (LIFE) study. GeroScience 2022;44:2757–70. 
    Crossref | PubMed
  42. Liu F, Austin TR, Schrack JA, et al. Late-life plasma proteins associated with prevalent and incident frailty: a proteomic analysis. Aging Cell 2023;22:e13975. 
    Crossref | PubMed
  43. Fielding RA, Atkinson EJ, Aversa Z, et al. Biomarkers of cellular senescence predict the onset of mobility disability and are reduced by physical activity in older adults. J Gerontol A Biol Sci Med Sci 2024;79:glad257. 
    Crossref | PubMed
  44. Englund DA, Sakamoto AE, Fritsche CM, et al. Exercise reduces circulating biomarkers of cellular senescence in humans. Aging Cell 2021;20:e13415. 
    Crossref | PubMed
  45. Farr JN, Xu M, Weivoda MM, et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med 2017;23:1072–9. 
    Crossref | PubMed
  46. Wan M, Gray-Gaillard EF, Elisseeff JH. Cellular senescence in musculoskeletal homeostasis, diseases, and regeneration. Bone Res 2021;9:41. 
    Crossref | PubMed
  47. Newman AB, Gottdiener JS, McBurnie MA, et al. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci 2001;56:M158–66. 
    Crossref | PubMed
  48. Nadruz W Jr, Kitzman D, Windham BG, et al. Cardiovascular dysfunction and frailty among older adults in the community: the ARIC study. J Gerontol A Biol Sci Med Sci 2017;72:958–64. 
    Crossref | PubMed
  49. Jia Y, Li D, Yu J, et al. Subclinical cardiovascular disease and frailty risk: the Atherosclerosis Risk in Communities study. BMC Geriatr 2022;22:321. 
    Crossref | PubMed
  50. Childs BG, Li H, van Deursen JM. Senescent cells: a therapeutic target for cardiovascular disease. J Clin Invest 2018;128:1217–28. 
    Crossref | PubMed
  51. Li H, Hastings MH, Rhee J, et al. Targeting age-related pathways in heart failure. Circ Res 2020;126:533–51. 
    Crossref | PubMed
  52. Kleipool EE, Hoogendijk EO, Trappenburg MC, et al. Frailty in older adults with cardiovascular disease: cause, effect or both? Aging Dis 2018;9:489–97. 
    Crossref | PubMed
  53. Anderson R, Lagnado A, Maggiorani D, et al. Length-independent telomere damage drives post-mitotic cardiomyocyte senescence. EMBO J 2019;38:e100492. 
    Crossref | PubMed
  54. Sharifi-Sanjani M, Oyster NM, Tichy ED, et al. Cardiomyocyte-specific telomere shortening is a distinct signature of heart failure in humans. J Am Heart Assoc 2017;6:e005086. 
    Crossref | PubMed
  55. Grootaert MOJ, Moulis M, Roth L, et al. Vascular smooth muscle cell death, autophagy and senescence in atherosclerosis. Cardiovasc Res 2018;114:622–34. 
    Crossref | PubMed
  56. Clayton ZS, Rossman MJ, Mahoney SA, et al. Cellular senescence contributes to large elastic artery stiffening and endothelial dysfunction with aging: amelioration with senolytic treatment. Hypertension 2023;80:2072–87. 
    Crossref | PubMed
  57. Orkaby AR, Lunetta KL, Sun FJ, et al. Cross-sectional association of frailty and arterial stiffness in community-dwelling older adults: the Framingham Heart Study. J Gerontol A Biol Sci Med Sci 2019;74:373–9. 
    Crossref | PubMed
  58. Lee SY, Chao CT, Huang JW, Huang KC. Vascular calcification as an underrecognized risk factor for frailty in 1783 community-dwelling elderly individuals. J Am Heart Assoc 2020;9:e017308. 
    Crossref | PubMed
  59. Erusalimsky JD. Vascular endothelial senescence: from mechanisms to pathophysiology. J Appl Physiol (1985) 2009;106:326–32. 
    Crossref | PubMed
  60. Erusalimsky JD, Kurz DJ. Endothelial cell senescence. Handb Exp Pharmacol 2006;(176 Pt 2):213–48. 
    Crossref | PubMed
  61. Burton DG, Matsubara H, Ikeda K. Pathophysiology of vascular calcification: pivotal role of cellular senescence in vascular smooth muscle cells. Exp Gerontol 2010;45:819–24. 
    Crossref | PubMed
  62. Childs BG, Zhang C, Shuja F, et al. Senescent cells suppress innate smooth muscle cell repair functions in atherosclerosis. Nat Aging 2021;1:698–714. 
    Crossref | PubMed
  63. Chou SM, Yen YH, Yuan F, et al. Neuronal senescence in the aged brain. Aging Dis 2023;14:1618–32. 
    Crossref | PubMed
  64. Shafqat A, Khan S, Omer MH, et al. Cellular senescence in brain aging and cognitive decline. Front Aging Neurosci 2023;15:1281581. 
    Crossref | PubMed
  65. Bussian TJ, Aziz A, Meyer CF, et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 2018;562:578–82. 
    Crossref | PubMed
  66. Ogrodnik M, Evans SA, Fielder E, et al. Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice. Aging Cell 2021;20:e13296. 
    Crossref | PubMed
  67. Mebratu YA, Soni S, Rosas L, et al. The aged extracellular matrix and the profibrotic role of senescence-associated secretory phenotype. Am J Physiol Cell Physiol 2023;325:C565–79. 
    Crossref | PubMed
  68. Qiao H, Chen M, Li S, et al. Poor lung function accelerates cognitive decline in middle-aged and older adults: evidence from the English Longitudinal Study of Ageing. Arch Gerontol Geriatr 2020;90:104129. 
    Crossref | PubMed
  69. Yang X, Cheng C, Ma W, Jia C. Longitudinal association of lung function with frailty among older adults: the English Longitudinal Study of Ageing. Eur Geriatr Med 2023;14:173–80. 
    Crossref | PubMed
  70. Wang G, Song A, Wang QA. Adipose tissue ageing: implications for metabolic health and lifespan. Nat Rev Endocrinol 2025;21:623–37. 
    Crossref | PubMed
  71. Xu M, Palmer AK, Ding H, et al. Targeting senescent cells enhances adipogenesis and metabolic function in old age. eLife 2015;4:e12997. 
    Crossref | PubMed
  72. Du K, Umbaugh DS, Ren N, Diehl AM. Cellular senescence in liver diseases: from molecular drivers to therapeutic targeting. J Hepatol 2025;84:194–212. 
    Crossref | PubMed
  73. Sanfeliu-Redondo D, Gibert-Ramos A, Gracia-Sancho J. Cell senescence in liver diseases: pathological mechanism and theranostic opportunity. Nat Rev Gastroenterol Hepatol 2024;21:477–92. 
    Crossref | PubMed
  74. Chanvillard L, Mason T, Ferenbach DA. Understanding and targeting senescence in kidney disease. Clin Kidney J 2025;18:sfaf190. 
    Crossref | PubMed
  75. Buchanan S, Combet E, Stenvinkel P, Shiels PG. Klotho, aging, and the failing kidney. Front Endocrinol (Lausanne) 2020;11:560. 
    Crossref | PubMed
  76. Kooman JP, Dekker MJ, Usvyat LA, et al. Inflammation and premature aging in advanced chronic kidney disease. Am J Physiol Ren Physiol 2017;313:F938–50. 
    Crossref | PubMed
  77. Guerville F, de Souto Barreto P, Taton B, et al. Estimated glomerular filtration rate decline and incident frailty in older adults. Clin J Am Soc Nephrol 2019;14:1597–604. 
    Crossref | PubMed
  78. Andersson R, Mejia-Ramirez E, Florian MC. Haematopoietic ageing in health and lifespan. Nat Cell Biol 2025;27:1398–410. 
    Crossref | PubMed
  79. Zhang W, Kong D, Zhang X, et al. T cell aging and exhaustion: mechanisms and clinical implications. Clin Immunol 2025;275:110486. 
    Crossref | PubMed
  80. Ng TP, Camous X, Nyunt MSZ, et al. Markers of T-cell senescence and physical frailty: insights from Singapore Longitudinal Ageing Studies. NPJ Aging Mech Dis 2015;1:15005. 
    Crossref | PubMed
  81. Sharma R. Perspectives on the dynamic implications of cellular senescence and immunosenescence on macrophage aging biology. Biogerontology 2021;22:571–87. 
    Crossref | PubMed
  82. Acosta JC, Banito A, Wuestefeld T, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 2013;15:978–90. 
    Crossref | PubMed
  83. Jeon OH, Mehdipour M, Gil TH, et al. Systemic induction of senescence in young mice after single heterochronic blood exchange. Nat Metab 2022;4:995–1006. 
    Crossref | PubMed
  84. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 2018;15:505–22. 
    Crossref | PubMed
  85. Pence BD. Growth differentiation factor-15 in immunity and aging. Front Aging 2022;3:837575. 
    Crossref | PubMed
  86. Papa MV, Ceolin C, Boschele F, et al. The stress-responsive cytokine GDF-15 and sarcopenia: a systematic review and meta-analysis on aging muscle decline. Mech Ageing Dev 2025;228:112117. 
    Crossref | PubMed
  87. Kamper RS, Nygaard H, Praeger-Jahnsen L, et al. GDF-15 is associated with sarcopenia and frailty in acutely admitted older medical patients. J Cachexia Sarcopenia Muscle 2024;15:1549–57. 
    Crossref | PubMed
  88. Xu J, Liu J, Tang J, et al. Plasma proteomic signature of risk and prognosis of frailty in the UK Biobank. GeroScience 2025;47:2365–81. 
    Crossref | PubMed
  89. Ferreira de Campos K, García-Esquinas E, Buño-Soto A, et al. Growth differentiation factor 15 predicts physical function impairment in Spanish older adults: a real-world prospective study. GeroScience 2025. 
    Crossref | PubMed
  90. Fuchs T, Trollor JN, Crawford J, et al. Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline: the Sydney Memory and Aging Study. Aging Cell 2013;12:882–9. 
    Crossref | PubMed
  91. Raffin J, Rolland Y, Parini A, et al. Association between physical activity, growth differentiation factor 15 and bodyweight in older adults: a longitudinal mediation analysis. J Cachexia Sarcopenia Muscle 2023;14:771–80. 
    Crossref | PubMed
  92. Kochlik B, Herpich C, Moreno-Villanueva M, et al. Associations of circulating GDF15 with combined cognitive frailty and depression in older adults of the MARK-AGE study. GeroScience 2024;46:1657–69. 
    Crossref | PubMed
  93. Gonzalez-Bautista E, Soto M, Abellan van Kan G, Delrieu J. Association between inflammatory biomarkers and the cognitive response to a multidomain intervention: secondary longitudinal analyses from the MAPT study. GeroScience 2025;47:5365–76. 
    Crossref | PubMed
  94. Osawa Y, Semba RD, Fantoni G, et al. Plasma proteomic signature of the risk of developing mobility disability: a 9-year follow-up. Aging Cell 2020;19:e13132. 
    Crossref | PubMed
  95. LeDrew M, Sadri P, Peil A, Farahnak Z. Muscle biomarkers as molecular signatures for early detection and monitoring of muscle health in aging. Nutrients 2025;17:2758. 
    Crossref | PubMed
  96. Cummings SR, Lui L-Y, Zaira A, et al. Biomarkers of cellular senescence and major health outcomes in older adults. GeroScience 2025;47:3407–15. 
    Crossref | PubMed
  97. Elenkov IJ, Iezzoni DG, Daly A, et al. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 2005;12:255–69. 
    Crossref | PubMed
  98. Argentieri MA, Xiao S, Bennett D, et al. Proteomic aging clock predicts mortality and risk of common age-related diseases in diverse populations. Nat Med 2024;30:2450–60. 
    Crossref | PubMed
  99. Fielder E, Wan T, Alimohammadiha G, et al. Short senolytic or senostatic interventions rescue progression of radiation-induced frailty and premature ageing in mice. eLife 2022;11:e75492. 
    Crossref | PubMed
  100. Murray KO, Mahoney SA, Ludwig KR, et al. Intermittent supplementation with fisetin improves physical function and decreases cellular senescence in skeletal muscle with aging: a comparison to genetic clearance of senescent cells and synthetic senolytic approaches. Aging Cell 2025;24:e70114. 
    Crossref | PubMed
  101. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBiomedicine 2019;47:446–56. 
    Crossref | PubMed
  102. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine 2019;40:554–63. 
    Crossref | PubMed
  103. Serra-Prat M, Sist X, Domenich R, et al. Effectiveness of an intervention to prevent frailty in pre-frail community-dwelling older people consulting in primary care: a randomised controlled trial. Age Ageing 2017;46:401–7. 
    Crossref | PubMed
  104. Sun X, Liu W, Gao Y, et al. Comparative effectiveness of non-pharmacological interventions for frailty: a systematic review and network meta-analysis. Age Ageing 2023;52:afad004. 
    Crossref | PubMed
  105. Lim H, Jani NDB, Pang WT, Lim ECW. Community-based exercises improve health status in pre-frail older adults: a systematic review with meta-analysis. BMC Geriatr 2024;24:589. 
    Crossref | PubMed
  106. Angulo J, El Assar M, Álvarez-Bustos A, Rodríguez-Mañas L. Physical activity and exercise: strategies to manage frailty. Redox Biol 2020;35:101513. 
    Crossref | PubMed
  107. Erusalimsky JD. Oxidative stress, telomeres and cellular senescence: what non-drug interventions might break the link? Free Radic Biol Med 2020;150:87–95. 
    Crossref | PubMed
  108. Zhang X, Englund DA, Aversa Z, et al. Exercise counters the age-related accumulation of senescent cells. Exerc Sport Sci Rev 2022;50:213–21. 
    Crossref | PubMed
  109. Ubaida-Mohien C, Moaddel R, Spendiff S, et al. Serum proteomic and metabolomic signatures of High versus Low physical function in octogenarians. Aging Cell 2025;24:e70002. 
    Crossref | PubMed
  110. Zhang P, Zhong J, Liu X, Sun W. The association between dynamic changes in vitamin D and frailty alterations: a prospective analysis of UK Biobank participants. J Cachexia Sarcopenia Muscle 2024;15:1722–32. 
    Crossref | PubMed
  111. Zhu H, Manson JE, Cook NR, et al. Vitamin D3 and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial. Am J Clin Nutr 2025;122:39–47. 
    Crossref | PubMed
  112. Kushner JA, Pandey M, Kohli SSS. Biomarker integration and biosensor technologies enabling AI-driven insights into biological aging. Front Aging 2025;6:1703698. 
    Crossref | PubMed
Previous Volume Article Next Volume Article